Reply to Deleterious effect of ifosfamide in leiomyosarcoma: Convergence of weak signals

Affiliations

¹ Department of Oncology, University of Turin, Turin, Italy.
² Sarcoma Unit, Division of Medical Oncology, Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Italy.
³ Statistics, European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
⁴ Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
⁵ Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Comment

Lorenzo D'Ambrosio et al. Cancer. 2020.

. 2020 Oct 15;126(20):4615-4616.

doi: 10.1002/cncr.33110. Epub 2020 Aug 7.

¹ Department of Oncology, University of Turin, Turin, Italy.
² Sarcoma Unit, Division of Medical Oncology, Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Italy.
³ Statistics, European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
⁴ Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
⁵ Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

No abstract available

Comment on

Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
D'Ambrosio L, Touati N, Blay JY, Grignani G, Flippot R, Czarnecka AM, Piperno-Neumann S, Martin-Broto J, Sanfilippo R, Katz D, Duffaud F, Vincenzi B, Stark DP, Mazzeo F, Tuchscherer A, Chevreau C, Sherriff J, Estival A, Litière S, Sents W, Ray-Coquard I, Tolomeo F, Le Cesne A, Rutkowski P, Stacchiotti S, Kasper B, Gelderblom H, Gronchi A; European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. D'Ambrosio L, et al. Cancer. 2020 Jun 1;126(11):2637-2647. doi: 10.1002/cncr.32795. Epub 2020 Mar 4. Cancer. 2020. PMID: 32129883
Deleterious effect of ifosfamide in leiomyosarcoma: Convergence of weak signals.
Penel N, Ryckewaert T, Pannier D. Penel N, et al. Cancer. 2020 Oct 15;126(20):4614-4615. doi: 10.1002/cncr.33111. Epub 2020 Aug 7. Cancer. 2020. PMID: 32767671 No abstract available.

1. Sleijfer S, Ouali M, van Glabbeke M, et al. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer. 2010;46:72-83.
1. Penel N, Italiano A, Isambert N, et al. Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin-containing chemotherapy. Ann Oncol. 2010;21:1361-1365.
1. D’Ambrosio L, Touati N, Blay JY, et al. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: a propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Cancer. 2020;126:2637-2647.
1. Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15:415-423.
1. Gronchi A, Palmerini E, Quagliuolo V, et al. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: final results of a randomized trial from Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) sarcoma groups. J Clin Oncol. 2020;38:2178-2186.